Array Biopharma (ARRY) Announces $100M Common Stock Offering
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
Array Biopharma (ARRY) Prices 18.4M Share Stock Offering for Proceeds of ~$115M
September 28, 2016 6:11 AM EDTArray BioPharma Inc. (Nasdaq: ARRY) announced the pricing of an underwritten public offering of 18,400,000 shares of its common stock at a public offering price of $6.25 per share. The gross proceeds from the sale of the shares, before underwriting discounts and commissions and offering expenses, are expected to be approximately $115 million. The offering is expected to close on or about October 3, 2016, subject to customary closing conditions. Array also granted the... More
Array Biopharma (ARRY) Gives Up Earlier Gains; Falls 2%
September 27, 2016 1:04 PM EDTYesterday's momentum stock du jour Array Biopharma (NASDAQ: ARRY) has broken lower after opening sharply higher. Shares are down 2% after gaining 81% on Monday.
... MoreArray BioPharma (ARRY) PT Raised to $8 at Jefferies
September 27, 2016 7:17 AM EDTJefferies analyst Eun Yang reiterated a Buy rating and raised his price target on Array BioPharma (NASDAQ: ARRY) to $8.00 (from $7.00) following successful Phase 3 COLUMBUS results yesterday.
Yang commented, "Given historical MEKi/BRAFi combo data in BRAFm melanoma, positive Ph3 COLUMBUS data is... More
Array Biopharma (ARRY) Adds to Gains; Shares Up 70%
September 26, 2016 2:03 PM EDTArray Biopharma (NASDAQ: ARRY) is pushing to the highs of the session. Shares are now up 70% after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic melanoma.
... MoreArray BioPharma (ARRY) PT Raised to $9 at Leerink Partners Following 'Impressive' Phase III Trial
September 26, 2016 12:49 PM EDTLeerink Partners analyst Michael Schmidt reiterated an Outperform rating and raised his price target on Array BioPharma (NASDAQ: ARRY) to $9.00 (from $6.00) after the company announced positive top-line results of the Phase III "COLUMBUS" trial evaluating the combination of binimetinib with encorafenib compared to Roche's vemurafenib in patients with BRAF+ metastatic... More
Array Biopharma (ARRY), Pierre Fabre Announce Encorafenib Combo Phase 3 Met Primary Endpoint in BRAF-Mutant Melanoma
September 26, 2016 7:01 AM EDTArray BioPharma (Nasdaq: ARRY) and Pierre Fabre jointly announced top-line results from Part 1 of the Phase 3 COLUMBUS (Combined LGX818 Used with MEK162 in BRAF Mutant Unresectable Skin Cancer) study evaluating LGX818 (encorafenib), a BRAF inhibitor, and MEK162... More